Acerus Pharmaceuticals (TSX: ASP) (OTCQB: ASPCF) is focused on the commercialization and development of innovative pharmaceutical products that improve the patient experience. Founded in 2008, Acerus has grown into a fully integrated, specialty pharmaceutical company with expertise in all stages of the pharmaceutical product life-cycle. The company is focused on men’s health (urology and andrology). The company’s foundational product is NATESTO®, a testosterone therapy based on patented nasal gel technology, approved in the United States, Canada and South Korea for the treatment of adult males diagnosed with hypogonadism. For more information, visit the company’s website at www.aceruspharma.com.
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.
NetworkNewsWire is part of the InvestorBrandNetwork.